Astrazeneca plc ADR (NASDAQ: AZN) has a price-to-earnings ratio that is above its average at 37.52x. The stock has a 36-month beta value of 0.47. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AZN is 3.10B, and at present, short sellers hold a 0.17% of that float. On October 22, 2024, the average trading volume of AZN was 4.50M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AZN) stock’s latest price update
The stock price of Astrazeneca plc ADR (NASDAQ: AZN) has dropped by -1.05 compared to previous close of 78.26. Despite this, the company has seen a fall of -0.85% in its stock price over the last five trading days. proactiveinvestors.co.uk reported 2024-10-21 that AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals’ (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis, a rare disease that damages nerves and leads to disability. The green light is based on a successful phase III trial, showing the drug improved patients’ nerve function and quality of life compared to a placebo.
AZN’s Market Performance
Astrazeneca plc ADR (AZN) has experienced a -0.85% fall in stock performance for the past week, with a -1.20% drop in the past month, and a -2.19% drop in the past quarter. The volatility ratio for the week is 0.87%, and the volatility levels for the past 30 days are at 0.94% for AZN. The simple moving average for the past 20 days is -0.41% for AZN’s stock, with a 3.91% simple moving average for the past 200 days.
Analysts’ Opinion of AZN
Goldman, on the other hand, stated in their research note that they expect to see AZN reach a price target of $97. The rating they have provided for AZN stocks is “Buy” according to the report published on May 30th, 2024.
AZN Trading at -4.31% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.67% of loss for the given period.
Volatility was left at 0.94%, however, over the last 30 days, the volatility rate increased by 0.87%, as shares surge +0.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.62% lower at present.
During the last 5 trading sessions, AZN fell by -0.85%, which changed the moving average for the period of 200-days by +12.59% in comparison to the 20-day moving average, which settled at $77.76. In addition, Astrazeneca plc ADR saw 14.98% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.78 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.13. The total capital return value is set at 0.12. Equity return is now at value 16.75, with 6.41 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.35. The debt to equity ratio resting at 0.82. The interest coverage ratio of the stock is 5.6.
Currently, EBITDA for the company is 13.91 billion with net debt to EBITDA at 1.79. When we switch over and look at the enterprise to sales, we see a ratio of 5.43. The receivables turnover for the company is 3.89for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
To sum up, Astrazeneca plc ADR (AZN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
